STB
BMRN icon

S&T Bank’s BioMarin Pharmaceuticals BMRN Stock Holding History

S&T Bank’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.83K Hold
32
– – ﹤0.01% 402
2026
Q1 		$1.81K Hold
32
– – ﹤0.01% 366
2025
Q4 		$1.9K Buy
+32
New +$1.74K ﹤0.01% 346
2025
Q3 		– Sell
-8
Closed -$440 – 489
2025
Q2 		$440 Buy
+8
New +$471 ﹤0.01% 457

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

S&T Bank's BMRN Position: Q2 2026 in Review

S&T Bank held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 32 shares worth $1.83K. The position accounts for ﹤0.01% of the portfolio, ranked #402.

S&T Bank first reported a position in BMRN in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.9K in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • S&T Bank held 32 shares of BioMarin Pharmaceuticals worth $1.83K as of Q2 2026.
  • S&T Bank left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of S&T Bank's portfolio in Q2 2026, its #402 holding.
  • S&T Bank first reported a position in BioMarin Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • S&T Bank's BioMarin Pharmaceuticals position peaked at $1.9K in Q4 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on S&T Bank's 13F filing for Q2 2026, filed 12 Aug 2026.